Facilitated By

San Antonio Medical Foundation

Trending Research

Top viewed research performed by San Antonio Bioscience Organizations


The goal of this trial is to compare if and for how long trastuzumab combined with either NeuVax (nelipepimut-S given with GM-CSF [sargramostim]) or sargramostim can help control the disease in patients with HER2 positive breast cancer. NeuVax is not FDA approved or commercially available. It is currently being used for research purposes only. Sargramostim is FDA approved and commercially available to help raise patients’ white blood cell counts after chemotherapy. Giving NeuVax or sargramostim to patients with HER2-positive breast cancer is investigational.

Cancer Insight, LLC
George Peoples

TxBiomed is helping to develop a safe and effective Ebola/Marburg combination vaccine based on recombinant adenoviral vectors to induce protective immunity.

Texas Biomedical Research Institute
Patterson, Jean L.